David A. Lipson

5.9k citations

144 papers · 3.9k indexed · 2 hit papers · h-index 28

Impact in

Pulmonary and Respiratory Medicine top 0.5%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Respiratory and Cough-Related Research
Physiology top 1%
- Asthma and respiratory diseases

Papers in

Pulmonary and Respiratory Medicine 102
- Chronic Obstructive Pulmonary Disease (COPD) Research 91
- Respiratory Support and Mechanisms 39
- Inhalation and Respiratory Drug Delivery 26
- Respiratory and Cough-Related Research 19
Issues, ethics and legal aspects 3

Co-authors: David A. Lomas Steven Pascoe Noushin Brealey Mark T. Dransfield Gerard J. Criner David Halpin Dave Singh MeiLan K. Han
Journals: International Journal of COPD (11 papers)Magnetic Resonance in Medicine (10 papers)CHEST Journal (10 papers)Respiratory Research (9 papers)Advances in Therapy (7 papers)
Partner nations: United States United Kingdom Denmark

In The Last Decade

David A. Lipson

140 papers receiving 3.8k citations

Hit Papers

align trajectories log scale

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD 2018 · 758 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2017 Critical Care

Peers

Countries citing papers authored by David A. Lipson

Since Specialization

Citations

This map shows the geographic impact of David A. Lipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Lipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Lipson more than expected).

Fields of papers citing papers by David A. Lipson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Lipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Lipson. The network helps show where David A. Lipson may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Lipson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Lipson Line = papers co-authored together David A. Lipson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD European Respiratory Journal ·زهرا آصفی, Fernando J. Martinez, Gerard J. Criner, Lee Tombs, David A. Lipson, David Halpin, Prakash Reddy BJ, Abhay Aradya, Robert A. Wise, Ravi Kalhan, Mark T. Dransfield	2024	3
2	Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England International Journal of COPD ·Leah B. Sansbury, David A. Lipson, Chanchal Bains, R E Cole, Kieran Rothnie, Afisi Ismaila	2022	9
3	EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON SEVERE EXACERBATION RATES COMPARED WITH TWICE-DAILY BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD: A POST HOC ANALYSIS OF THE FULFIL STUDY CHEST Journal ·Reynold A. Panettieri, Michael G. A. Wilson, Carlos A. Camargo, Tariq Cheema, Antônio Augusto Schmitt Júnior, Stanley B. Fiel, Renu Jain, Dawn Midwinter, Javier Uranga, Byron Thomashow, David A. Lipson	2021	0
4	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·Byron Thomashow, Marjorie Stiegler, Gerard J. Criner, Mark T. Dransfield, David Halpin, MeiLan K. Han, Peter Lange, Fernando J. Martínez, Dawn Midwinter, Dave Singh, Maggie Tabberer, Robert A. Wise, David A. Lipson, Paul Jones	2021	6
5	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial Advances in Therapy ·Leif Bjermer, I. Boucot, Claus Vogelmeier, François Maltais, Paul Jones, Lee Tombs, Chris Compton, David A. Lipson, Edward Kerwin	2021	4
6	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis ERJ Open Research ·MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David Halpin, Christine Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martínez, Robert A. Wise, Ian Naya, Dave Singh	2021	7
7	<p>Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study</p> International Journal of COPD ·Nanshan Zhong, Jinping Zheng, Sang Haak Lee, David A. Lipson, Nofumi KADOTA, Idoxis Rachidy	2020	4
8	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial American Journal of Respiratory and Critical Care Medicine ·MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David Halpin, Christine Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Robert A. Wise, Dave Singh, Fernando J. Martínez	2020	20
9	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·David A. Lipson, Courtney Crim, Gerard J. Criner, Nicola C. Day, Mark T. Dransfield, David Halpin, MeiLan K. Han, Christine Jones, Sally Kilbride, Peter Lange, David A. Lomas, Sally Lettis, Guanhong Wu, Neil Martin, Dawn Midwinter, Andrea Morris, Steven Pascoe, Dave Singh, Robert A. Wise, Fernando J. Martínez	2020	146
10	The effect of exacerbation history on outcomes in the IMPACT trial European Respiratory Journal ·David Halpin, Mark T. Dransfield, MeiLan K. Han, Carl E. Jones, Sally Kilbride, Peter Lange, David A. Lipson, David A. Lomas, Fernando J. Martínez, Steve Pascoe, Dave Singh, Robert A. Wise, Gerard J. Criner	2020	25
11	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial The Lancet Respiratory Medicine ·Steven Pascoe, Neil Barnes, Guy Brusselle, Chris Compton, Gerard J. Criner, Mark T. Dransfield, David Halpin, MeiLan K. Han, Benjamin Hartley, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Fernando J. Martínez, Alberto Papi, Nicolás Roche, Ralf J.P. van der Valk, Robert A. Wise, Dave Singh	2019	153
12	Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis Advances in Therapy ·Ian Naya, Lee Tombs, David A. Lipson, Chris Compton	2018	11
13	FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease American Journal of Respiratory and Critical Care Medicine ·David A. Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Nicholas Locantore, David A. Lomas, Andrea Ludwig-Sengpiel, Rajat Mohindra, Maggie Tabberer, Chang‐Qing Zhu, Steven Pascoe	2017	226
14	Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial Advances in Therapy ·Afisi Ismaila, Ruby Birk, Dhvani Shah, Shiyuan Zhang, Noushin Brealey, Nancy Risebrough, Maggie Tabberer, Chang‐Qing Zhu, David A. Lipson	2017	13
15	A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol European Respiratory Journal ·Steven Pascoe, David A. Lipson, Nicholas Locantore, Helen Barnacle, Noushin Brealey, Rajat Mohindra, Mark T. Dransfield, Ian Pavord, Neil Barnes	2016	60
16	Postanoxic Myoclonus: Two Case Presentations and Review of Medical Management Archives of Physical Medicine and Rehabilitation ·Adrian Budhram, David A. Lipson, Shanker Nesathurai, David T. Harvey, Michel P. Rathbone	2013	8
17	Perfusion Scintigraphy and Patient Selection for Lung Volume Reduction Surgery American Journal of Respiratory and Critical Care Medicine ·Divay Chandra, David A. Lipson, Eric A. Hoffman, John Hansen‐Flaschen, Frank C. Sciurba, Malcolm M. DeCamp, John J. Reilly, George R. Washko	2010	30
18	Hyperpolarized helium-3 MR imaging of pulmonary function Radiologic Clinics of North America ·Masaru Ishii, Martin C. Fischer, Kiarash Emami, Abass Alavi, Zebulon Z. Spector, Jiangsheng Yu, James E. Baumgardner, Maxim Itkin, Stephen Kadlecek, Jianliang Zhu, Michael Bono, Warren B. Gefter, David A. Lipson, Joseph B. Shrager, Rahim R. Rizi	2005	14
19	Pulmonary ventilation and perfusion scanning using hyperpolarized helium‐3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patients Magnetic Resonance in Medicine ·David A. Lipson, David A. Roberts, John Hansen‐Flaschen, T. Gentile, G. L. Jones, A. K. Thompson, Ivan Dimitrov, Harold I. Palevsky, John S. Leigh, Mitchell D. Schnall, A. Bure	2002	41
20	Giant Gastric Ulcers and Risk Factors for Gastroduodenal Mucosal Disease in Orthotopic Lung Transplant Patients Digestive Diseases and Sciences ·David A. Lipson, Jesse A. Berlin, Harold I. Palevsky, Robert M. Kotloff, Gregory Tino, Joseph E. Bavaria, Larry R. Kaiser, William B. Long, David C. Metz, Gary R. Lichtenstein	1998	11

About David A. Lipson

David A. Lipson is a scholar working on Pulmonary and Respiratory Medicine, Issues, ethics and legal aspects, Physiology, Spectroscopy and Critical Care and Intensive Care Medicine, having authored 144 papers that have together received 3.9k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (91 papers), Asthma and respiratory diseases (52 papers), Respiratory Support and Mechanisms (39 papers), Inhalation and Respiratory Drug Delivery (26 papers), Atomic and Subatomic Physics Research (23 papers), Respiratory and Cough-Related Research (19 papers), Advanced NMR Techniques and Applications (18 papers) and Advanced MRI Techniques and Applications (16 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.5k citations), Physiology (1.5k citations), Issues, ethics and legal aspects (58 citations), Infectious Diseases (372 citations) and Spectroscopy (284 citations). David A. Lipson has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include David A. Lomas, Steven Pascoe, Noushin Brealey, Mark T. Dransfield, Gerard J. Criner, David Halpin, Dave Singh, MeiLan K. Han, Robert A. Wise and Fernando J. Martínez. Their work appears in journals such as International Journal of COPD, Magnetic Resonance in Medicine, CHEST Journal, Respiratory Research and Advances in Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact